Spero Therapeutics, Inc.

SPROSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1701108

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$933.0K	$2.5M	$3.1M	$258.0K	$4.7M
Research and Development Expense	$51.4M	$47.6M	$64.5M	$67.0M	$65.8M
Operating Expenses	$82.3M	$95.7M	$106.2M	$88.4M	$81.4M
Operating Income (Loss)	$21.5M	-$42.2M	-$88.0M	-$79.1M	-$63.2M
Nonoperating Income (Expense)	$3.9M	-$4.2M	-$1.8M	$833.0K	$2.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$25.4M	-$46.4M	-$89.8M	-$78.3M	—
Income Tax Expense (Benefit)	$2.6M	$0.00

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$182.4M	$124.8M	$171.1M	$153.5M	$106.1M
Assets, Current	$131.2M	$113.6M	$157.9M	$139.1M	$95.4M
Cash and Cash Equivalents, at Carrying Value	$76.3M	$109.1M	$112.6M	$85.2M	$29.7M
Liabilities	$75.5M	$48.9M	$82.8M	$21.4M	$31.5M
Liabilities, Current	$37.2M	$21.6M	$18.7M	$14.3M	$26.7M
Accounts Payable, Current	$1.4M	$617.0K	$1.1M	$1.2M	$4.1M
Stockholders' Equity Attributable to Parent	$75.9M	$88.3M	$132.0M	$74.6M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$33.0M	-$7.7M	-$64.3M	-$85.9M	-$50.0M
Net Cash Provided by (Used in) Investing Activities	—	$33.8M	$7.7M	$10.5M	$29.5M
Net Cash Provided by (Used in) Financing Activities	$221.0K	-$29.6M	$84.0M	$130.9M	$16.1M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	$314.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)